A Systematic Review of Nonpharmacological Exercise-Based Rehabilitative Interventions in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

M. Jarden

Department of Haematology, The University Hospital of Copenhagen, The University Hospital’s Centre for Nursing and Care Research, Copenhagen Denmark

1. Introduction

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an established treatment. More than 15,000 procedures are performed worldwide each year for a number of hematological malignancies such as acute myeloid and lymphoid leukemia, and bone marrow failure syndromes (Gratwohl et al. 2002; Frassoni, 2004). It is predicted that transplantation rates for allo-HSCT will continue at the same or higher level in the immediate future (Gratwohl et al. 2002). Despite clinical cure in 20-70% of all patients, depending on disease presentation, long term sequelae of immunosuppression, chemotherapy toxicities and graft-versus-host disease (GvHD) debilitate a large number of patients (Gratwohl et al. 2002). Moderate to severe GvHD develops in 40-50% of patients undergoing allo-HSCT (Bearman et al. 1988; Weisdorf et al. 1990; Roy et al. 1992; Hings et al. 1994). Factors limiting the efficacy of this treatment are death due to recurrence or treatment-related death due to infection or organ failure in the cytopenia and later immunosuppressed phase immediately post-HSCT. Over the last decades, the cumulative effects of improvements in supportive care, drug dosing, stem cell technology and prophylaxis of GvHD have led to an increased number of complete remissions (Devergie, 2004). However, with the increasing number of transplants performed and the growing number of survivors, a shift in clinical focus from not only improving survival but also improving short and long-term quality of life has emerged (Andrykowski et al. 1995). Patients in the treatment and recovery phase of HSCT commonly experience adverse physical and emotional reactions. Fatigue and muscle weakness can limit ability to accomplish activities of daily living. Additionally, depression, anxiety, fear, and frustration add to the difficulties of recovering from HSCT (Syrjala et al. 1993; Andrykowski et al. 1995). Several studies confirm that high levels of physical and psychological stress have been observed in patients prior to and at the start of HSCT and during follow-up periods (Baker et al. 1997; Molassiotis & Morris, 1997; McQuellon et al. 1998; Fife et al. 2000). The mechanisms are not fully known, but it is assumed that several factors such as total body...
irradiation (TBI), chemotherapy, GvHD, infections, long-term inactivity or bed rest and side-effects from medication can contribute to the physical and emotional weakening of the patient. Recipients of allo-HSCT with low Vitamin D levels and low bone mineral density were likely to have received corticosteroids, have experienced GVHD and an elevated parathyroid hormone level (Sproat et al. 2011; Massenkeil et al. 2001). Vitamin D insufficiency and deficiency can cause osteomalacia, bone pain, muscle weakness, musculoskeletal pain, headache, fatigue, and may precipitate or exacerbate osteopenia and osteoporosis and increase risk of skeletal fracture (Knutsen et al. 2010; Sproat et al. 2011).

Patients that have undergone HSCT experience treatment-related symptoms during and after treatment that can affect health related quality of life (HR-QOL). Patients experience multiple somatic, affective and cognitive symptoms during and after aggressive cancer treatment, where eleven to thirteen simultaneously occurring symptoms have been reported (Portenoy et al. 1994). During hospitalization for standard allo-HSCT, patients are typically on prolonged bed rest, and experience complications from the myeloablative treatment, ie. acute GvHD, side effects from medications (immunosuppression & steroids), frequent infections and psychological reactions that can be debilitating. It is reported that HR-QOL is lowest during inpatient time (Grulke et al. 2011). The most commonly reported symptoms are fatigue, diarrhea, insomnia, poor appetite, diminished concentration, mouth dryness, dyspnoea, loss of hair and poor body image perception (Jarden et al. 2009; Molassitis et al. 1997; Larsen et al. 2007). After HSCT, fatigue, dyspnoea and insomnia remain at elevated levels (Grulke et al. 2011). Psychosocial wellbeing after transplant is influenced by mucositis toxicity, and other side effects, and psychological factors as anxiety, distress and social support have a significant impact on how severely patients experience mouth pain (Schulz-Kindermann et al. 2002). Fatigue is one of the most frequent and distressful side effects reported by patients who have undergone HSCT (Jarden et al. 2009; So et al. 2003), and it has been shown that physical activity decreased and this decline coincided with diminished physical, emotional, role and cognitive functioning during the initial post transplantation period (Danaher et al. 2006). Bevans et al. found that patients experienced multiple symptoms and high symptom distress after allo-HSCT conditioning (Bevans et al. 2008). Further, fatigue was the main symptom interfering with daily life in 79% of patients (Molassiotis & Morris, 1999), and in 11% of patients at 100 days post allo-HSCT (Bevans et al. 2008). Loss of physical strength seem to be more pronounced in patients on corticosteroid treatment, and the causes of an impairment of physical performance are not fully understood, though low activity levels have been suggested to be a substantial contributor (Carlson et al. 2006). One study in patients undergoing HSCT showed a correlation between the number of symptoms experienced and poor functional status and general health (Larsen et al. 2007) and in another study, changes in HRQoL could be explained entirely by changes in functional limitations and somatic symptoms (Broers et al. 2000). Further, symptom bother from GVHD had a direct effect on functional performance (Mitchell et al. 2010). A Danish study found patients prior to allo-HSCT to have lower VO\textsubscript{2} max scores and elevated fatigue levels than the normal population, and these scores were unchanged six months after transplantation (Kalo et al. 2007). Furthermore, persons diagnosed with hematological disease have difficulty returning to the work force (deBoer et al. 2008) and have an increased risk for early retirement (Carlsen et al. 2008), while unemployed leukaemia patients, especially those with lower social support have significantly elevated levels of stress, anxiety, and depression (deBoer et al. 2008). In HSCT, predictors of slower return to work
include physical dysfunction and female gender (Kirchhoff AC et al. 2010). Maintaining daily function and reducing fatigue and treatment-related symptoms can be important goals and there is therefore, a continued need for nonpharmacological strategies that address the specific impairments experienced by patients undergoing allo-HSCT.

There is a rapidly increasing literature on the effects of exercise on cancer rehabilitation, especially for breast cancer patients, on whom the majority of research has been conducted (Courneya et al. 2011, Conn et al. 2006). Despite that physical exercise showed positive effects on cardiorespiratory fitness, treatment-related symptoms and physiological effects, the extent of these positive results still need to be established. A qualitative and quantitative review and meta-analysis found only small to moderate effect of physical activity interventions on these outcomes (Schmitz et al. 2005; Conn et al. 2006). Physical activity is reported as being well tolerated in cancer survivors during and after treatment, however, conclusions about adverse effects are inconclusive (Schmitz et al. 2005). Recent guidelines for exercise prescription for cancer survivors from the American College of Sports Medicine (Schmitz et al. 2010) report no contraindication for starting an exercise program in patients undergoing either autologous or allogeneic HSCT – however, issues regarding, the ideal time for starting a program safely and effectively, type of program, frequency, intensity and duration is not confirmed, especially in relation to the HSCT treatment trajectory. Exercise has been proposed as a nonpharmacologic adjuvant therapy to combat the physiological and psychological symptoms of HSCT (Wiskemann & Huber, 2008). However, little work exists in utilizing exercise interventions specifically in the allo-HSCT setting. It is documented that there is a decline in exercise levels in cancer patients from prediagnosis to postdiagnosis (Courneya et al.1997) and more specifically, a low level of “naturally-occurring” exercise amongst patients undergoing HSCT is reported, suggesting that a structured intervention may be necessary in order to promote exercise in this population (Courneya et al. 2000). The majority of the earlier research done in adult patients with hematological disease is in the context of high dose chemotherapy with stem cell support (autologous HSCT or HD-SCS). To date, there are eight published studies that incorporated exercise regimes in the high dose chemotherapy-stem cell support context (HD-SCS) (Coleman et al. 2003; Decker et al 1989; Hayes et al. 2003, Dimeo et al. 1996, 1997, 1999, 2003, including one on-going study (Peerson et al. 2010), and five studies in mixed HD-SCS and allo-HSCT populations (Dimeo et al. 1999, Baumann et al. 2005; Wilson et al. 2005, Knols et al. 2010, Danaher Hacker et al. 2011). There are however fundamental and important differences in the two types of treatment (HD-SCS and allo-HSCT) including the conditioning regimes, i.e. total body irradiation in allo-HSCT, and origin of stem cells, i.e. patients undergoing HD-SCS are supported with their own stem cells, and therefore the donor related challenges (GvHD) in allo-HSCT are not present, and lastly, the overall duration of hospitalization for HD-SCS is much shorter compared to allo-HSCT. One 3 year prospective study, found that patients undergoing HD-SCS had better self-rated physical function (symptomotology, physical status and energy level) as compared to the allo-HSCT group (Prieto et al 2005). The HD-SCS and mixed group (HD-SCS and allo-HSCT, and age) exercise-based study sizes ranged between 12-70 participants. There are five randomized trials (Peerson et al. 2010; Baumann et al. 2005; Coleman et al. 2003; Hayes et al. 2004; Dimeo et al. 1996), one study used a minimization procedure (Knols et al. 2010) and six single-group trials (Danaher Hacker et al. 2011; Wilson et al. 2005; Decker et al 1989; Dimeo et al.
Exercise was tested during hospitalization in three studies (Baumann et al. 2005; Dimeo et al. 1996; 2003), one study during hospitalization and continued to outpatient (Dimeo 1999), and eight studies after hospital discharge (outpatient and home based programs) (Wilson et al. 2005; Decker et al. 1989; Coleman et al. 2003; Hayes et al. 2004; Dimeo et al. 1997, Knols et al. 2010; Peerson et al. 2010; Danaher Hacker et al. 2011). Feasibility was established, no adverse events registered and beneficial effects were reported on aerobic capacity (Hayes et al. 2004; Dimeo et al. 2003; Dimeo et al. 1996); muscle strength (Hayes et al. 2004; Knols et al. 2010), body composition (Coleman et al. 2003; Hayes et al. 2003), immunological function (Dimeo et al. 1997; Hayes et al. 2003; Knols et al. 2010), treatment-related symptoms i.e. fatigue (Dimeo et al. 1999; Wilson et al. 2005) and HRQoL (Wilson et al. 2005; Hayes et al. 2004). These positive and potentially important results for HD-SCS and mixed groups are encouraging, but we need to look exclusively at the allo-HSCT adult patient group in order to evaluate the role and impact of exercise rehabilitation in this treatment context alone. The primary objective of the systematic review is to summarize the exercise-based rehabilitative interventions in adults with haematological disease undergoing allogeneic hematopoetic stem cell transplantation (allo-HSCT) on feasibility and safety, and effectiveness related to physical and functional capacity, health related quality of life, treatment-related symptoms and medical related outcomes.

2. Method

The systematic literature search is based on PRISMA guidelines (preferred reporting items for systematic reviews and metaanalyses) developed from Cochrane Collaboration (Moher D et al. 2009). This review includes 1) a systematic literature search with the identification of all intervention trials in adult patients in the allo-HSCT setting during the past 25 years, 2) a uniform presentation of all trials and a synthesis of the characteristics and findings, 3) an appraisal of the methodological quality of the trials, 4) a summary and 5) conclusions and future research.

2.1 Search strategy and data extraction

The systematic literature review covers 25 years of research: 1986 – 2011 (Table 1). Searches were carried out in MEDLINE and EMBASE using search items bone marrow cell transplantation, bone marrow transplantation, stem cell transplantation, physical activity, physical fitness and exercise. Identified articles were searched for additional references. The search was limited to include randomized controlled trials (RCT), controlled clinical trials, adults and English articles. Eligibility criteria are shown in Table 2. Only studies that included patients from the allogeneic setting are included in this review. Studies that included patients in either the auto-HSCT / HD-SCS setting or mixed settings (both autologous and allogeneic) were excluded, though compiled in the literature search for background and reference purposes. Full articles were obtained for remaining abstracts and information was extracted from identified articles and organized under the following headings: authors, sample (n, type of treatment), age, design and study period, exercise-based intervention, duration, frequency/intensity, and results (Table 3). All articles were independently reviewed and appraised for rigor of method and analysis.
### Table 1. Results of a systematic literature search with keywords

<table>
<thead>
<tr>
<th>Date</th>
<th>Search</th>
<th>Limits</th>
<th>Database</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>1/7/2011</td>
<td>&quot;Bone Marrow Cell Transplantation&quot; OR &quot;Bone Marrow Transplantation&quot; OR &quot;Stem Cell Transplantation&quot; AND (Allogeneic OR Autologous) AND (&quot;Physical activity&quot; OR &quot;Physical fitness&quot; OR Exercise) AND (English AND (&quot;1986/01/01&quot; : &quot;2011/07/01&quot;)</td>
<td>English, Publication date from 1986/01/01 to 2011/07/01</td>
<td>Medline (NLM)</td>
<td>90</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Date</th>
<th>Search</th>
<th>Limits</th>
<th>Database</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>1/7/2011</td>
<td>&quot;Bone Marrow Cell Transplantation&quot; OR &quot;Bone Marrow Transplantation&quot; OR &quot;Stem Cell Transplantation&quot; AND (Allogeneic OR Autologous) AND (&quot;Physical activity&quot; OR &quot;Physical fitness&quot; OR Exercise) AND (English AND (&quot;1986/01/01&quot; : &quot;2011/07/01&quot;)</td>
<td>English, Publication date from 1986/01/01 to 2011/07/01</td>
<td>Medline (NLM)</td>
<td>90</td>
</tr>
</tbody>
</table>

### Inclusion criteria
- Journal articles reporting primary research of exercise-based intervention studies prior to, during or after allo-HSCT
- Randomized clinical trials or controlled studies
- Participants ≥ 18 years
- Recipients of allo-HSCT for a hematologic disease
- Published in English between 1986 and 2011

### Exclusion criteria
- Studies that include auto-HSCT/HD-SCT
- Studies that include a mixed population of auto-HSCT and allo-HSCT
- Review articles or case study
- Clinical reports
- Dissertations
- Conference abstracts
- Editorials or letters to the editor

Allo-HSCT indicates allogeneic stem cell transplantation; auto-SCT, autologous stem cell transplantation; HD-SCT, high dose chemotherapy with stem cell support

Table 2. Eligibility criteria
<table>
<thead>
<tr>
<th>Authors</th>
<th>Sample</th>
<th>Age</th>
<th>Design and study period</th>
<th>Exercise-based Intervention</th>
<th>Duration</th>
<th>Frequency/Intensity</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cunningham et al.</td>
<td>N=60</td>
<td>25 years* (range 14-41)</td>
<td>RCT - three groups</td>
<td>Supervised IG1 and IG2: strength resistance training</td>
<td>5 weeks</td>
<td>IG1 3 days/week IG2 5 days/week</td>
<td>Program compliance: not reported.</td>
</tr>
<tr>
<td>(1986)</td>
<td>Attrition 25%</td>
<td></td>
<td>IG1=resitive exercise IG2=resitive exercise CG= usual care/ no exercise</td>
<td></td>
<td></td>
<td>30 min per session</td>
<td>Safety: muscle and joint stiffness reported in CG (5 of 5 patients).</td>
</tr>
<tr>
<td></td>
<td>30 completers: IG1=10</td>
<td></td>
<td>In-patient</td>
<td>Contraindication for exercise: Platelets &lt;10,000/mm³ Bleeding</td>
<td></td>
<td>Resistive exercise</td>
<td>Independent mean active days for IG1 19.8, IG2 19.5 and CG 18.7.</td>
</tr>
<tr>
<td></td>
<td>IG2=10</td>
<td></td>
<td>Cardiac arrhythmia Temp: &gt;39.5°C</td>
<td></td>
<td></td>
<td>with 15 repetitions of</td>
<td>Pre-post No significant intergroup differences in body composition</td>
</tr>
<tr>
<td></td>
<td>CG=10</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>8 different exercises</td>
<td>CG ↓ creatinine excretion (p=0.039)</td>
</tr>
<tr>
<td></td>
<td>Allo-HSCT</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>IG1 and IG2 → creatinine excretion</td>
</tr>
<tr>
<td></td>
<td>Hematopoietic</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>diagnoses: AML, ALL - all</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>receiving TPN</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mello M, et al.</td>
<td>N=32</td>
<td>29 years* (range 18-44)</td>
<td>RCT - two groups</td>
<td>IG: active ROM exercise (5 exercises), muscle stretching (3 muscle groups) and a modified treadmill walking program</td>
<td>6 weeks</td>
<td>5 days / week 40 min per session</td>
<td>Program compliance: not reported.</td>
</tr>
<tr>
<td>(2003)</td>
<td>Attrition 44%</td>
<td></td>
<td>During HSCT</td>
<td>Contraindication for exercise:</td>
<td></td>
<td>Aerobic training; 5 sets of 3 min walking at a comfortable pace</td>
<td>Safety: No adverse events</td>
</tr>
<tr>
<td></td>
<td>18 completers: IG=9</td>
<td></td>
<td>IG=exercise program CG=usual care</td>
<td>Platelets&lt;10 mg/dl</td>
<td></td>
<td>with 3 min rest between sets Progression to 2 sets of 10 min walking</td>
<td>Muscle strength: Pre-post No significant intergroup differences</td>
</tr>
<tr>
<td></td>
<td>CG=9</td>
<td></td>
<td>In-patient/Outpatient</td>
<td>at a comfortable pace alternated with 20 min walking at</td>
<td></td>
<td>at accelerated pace with HR no higher than 70% of MHR.</td>
<td>Significant Intragroup differences:</td>
</tr>
<tr>
<td></td>
<td>Allogeneic HSCT</td>
<td></td>
<td>Exercise initiated after neutroph engraftment and continued in the outpatient facility</td>
<td>accelerated pace with HR no higher than 70% of MHR.</td>
<td></td>
<td>Mild to moderate intensity</td>
<td>CG ↓ Shoulder (abductors &amp; flexors)</td>
</tr>
<tr>
<td></td>
<td>Hematopoietic</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>CG ↓ Elbow (excl. DM extensors)</td>
</tr>
<tr>
<td></td>
<td>diagnoses: CML, AML, SAA, NII, MDS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>CG ↓ and IG ↓ Knee (flexors)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>CG ↓ Ankle (flexors)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Authors</td>
<td>Sample</td>
<td>Age</td>
<td>Design and study period</td>
<td>Exercise-based Intervention</td>
<td>Duration</td>
<td>Frequency/Intensity</td>
<td>Results</td>
</tr>
<tr>
<td>------------------</td>
<td>----------------------------------</td>
<td>------------------</td>
<td>-------------------------</td>
<td>-----------------------------</td>
<td>----------</td>
<td>---------------------</td>
<td>-------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Kim et al.</td>
<td>N=42</td>
<td>33.6 years*</td>
<td>RCT – two groups</td>
<td>Supervised</td>
<td>6 weeks</td>
<td>30 minutes daily</td>
<td>Program compliance: not reported</td>
</tr>
<tr>
<td></td>
<td>35 completers:</td>
<td></td>
<td>CG: usual care</td>
<td>10 min</td>
<td></td>
<td></td>
<td>Hematological Outcomes: Pre-post</td>
</tr>
<tr>
<td></td>
<td>IG=18</td>
<td></td>
<td>In-patient</td>
<td>Relaxation breathing</td>
<td></td>
<td></td>
<td>IG: ↑ lymphocyte count (not significant, however interaction between groups and times significant (p=0.031).</td>
</tr>
<tr>
<td>Allo-HSCT</td>
<td>CG=17</td>
<td></td>
<td>During entire</td>
<td>10 min</td>
<td></td>
<td></td>
<td>CG: ↓ lymphocyte count (p&lt;0.05)</td>
</tr>
<tr>
<td></td>
<td>Hematopoietic</td>
<td></td>
<td>hospitalization</td>
<td>ROM, stretching and</td>
<td></td>
<td></td>
<td>Mathematical Measures: Pre-post / Post / Follow-up</td>
</tr>
<tr>
<td></td>
<td>diagnoses: AML, ALL, SAA</td>
<td></td>
<td></td>
<td>relaxation 10 min</td>
<td></td>
<td></td>
<td>Intergroup significant changes</td>
</tr>
<tr>
<td>Carlson et al.</td>
<td>N=12</td>
<td>47 (range</td>
<td>QE (No control group)</td>
<td>Supervised</td>
<td>12 weeks</td>
<td>3 days/week</td>
<td>Program compliance: 89%</td>
</tr>
<tr>
<td>(2006)</td>
<td>Attrition 0% (12 completers)</td>
<td>28-55)</td>
<td>Outpatient</td>
<td>Individualized</td>
<td></td>
<td></td>
<td>Safety: No adverse events</td>
</tr>
<tr>
<td>Allo-HSCT</td>
<td>Hematopoietic</td>
<td></td>
<td>After allo-HSCT: 39</td>
<td>endurance training on</td>
<td></td>
<td></td>
<td>Physiological Outcomes: Pre-post</td>
</tr>
<tr>
<td></td>
<td>diagnoses: CLL, CML, AML, NHL,</td>
<td></td>
<td>months (range 9-92</td>
<td>cycle ergometer</td>
<td></td>
<td></td>
<td>↑ St.V (p&lt;0.005), ↓ HR (p&lt;0.005) and</td>
</tr>
<tr>
<td></td>
<td>FL, MDS</td>
<td></td>
<td>months)</td>
<td></td>
<td></td>
<td></td>
<td>↓ RPE (p&lt;0.005)</td>
</tr>
<tr>
<td>DeFor et al.</td>
<td>N=100</td>
<td>47 years*</td>
<td>RCT – two groups</td>
<td>Not supervised –</td>
<td>14 weeks</td>
<td>Daily</td>
<td>Program compliance: 100% for</td>
</tr>
<tr>
<td>2007</td>
<td>Attrition 15%</td>
<td>(range 18-68)</td>
<td>IG: walking regime</td>
<td>compliance was</td>
<td></td>
<td></td>
<td>10 patients (24%), 28 (68%) and 24 (62%) patients exercised</td>
</tr>
<tr>
<td></td>
<td>85 completers:</td>
<td></td>
<td>CG: no formal exercise</td>
<td>encouraged three times /wk</td>
<td></td>
<td></td>
<td>at least 5 times/wk for at least 15 min. during hospitalization, and</td>
</tr>
<tr>
<td></td>
<td>IG=43</td>
<td></td>
<td></td>
<td>during hospitalization</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CG=42</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Authors</td>
<td>Sample</td>
<td>Age</td>
<td>Design and study period</td>
<td>Exercise-based Intervention</td>
<td>Duration</td>
<td>Frequency/Intensity</td>
<td>Results</td>
</tr>
<tr>
<td>-----------------</td>
<td>---------------------------------</td>
<td>--------------</td>
<td>-------------------------</td>
<td>----------------------------------------------------</td>
<td>----------</td>
<td>--------------------</td>
<td>---------------------------------------------</td>
</tr>
<tr>
<td>Jarden et al.</td>
<td>N= 42 patients</td>
<td>40.8 years*</td>
<td>RCT - two groups</td>
<td>Supervised</td>
<td>6 weeks</td>
<td>5 days/week</td>
<td>after discharge, respectively.</td>
</tr>
<tr>
<td></td>
<td>Attrition 19%</td>
<td>(range 18-60)</td>
<td>IG: exercise-based intervention</td>
<td>Graded exercise on cycle ergometer, resistance training with hand and ankle weights (9 muscle groups), ROM and stretching (6 exercises), relaxation training, discipline and psycho-education</td>
<td></td>
<td></td>
<td>Safety: Not reported</td>
</tr>
<tr>
<td></td>
<td>34 completers</td>
<td>CG: 38 (18-55)</td>
<td>CG: standard care (PT)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>lG=17</td>
<td></td>
<td>In-patient</td>
<td>Initiated on first day of admission to discharge</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CG=17</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Allo-HSCT</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hematopoietic diagnoses:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CML, AML, ALL, AA, MDS, WM, PNH, MF</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CG: 49 (22-64)</td>
<td></td>
<td>In-patient/home-based</td>
<td>Inpatient: endurance training - walking regime on treadmill Home-based: endurance training - walking regime</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>From day of admission to 100 days</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Authors</td>
<td>Sample</td>
<td>Age</td>
<td>Design and study period</td>
<td>Exercise-based Intervention</td>
<td>Duration</td>
<td>Frequency/Intensity</td>
<td>Results</td>
</tr>
<tr>
<td>---------</td>
<td>--------</td>
<td>-----</td>
<td>--------------------------</td>
<td>-----------------------------</td>
<td>----------</td>
<td>--------------------</td>
<td>---------</td>
</tr>
<tr>
<td>Shelton et al. 2009</td>
<td>N=61 Attrition 13% 53 completers: IG1=26 IG2=27 Allo-HSCT Hematopoietic diagnoses: AML, ALL, CML, CLL, NH, HD, Lymphoma</td>
<td>46.3 years* (range 22-70)</td>
<td>RCT – two groups IG1: Supervised IG2: Self directed Out-patient After allo-HSCT and within the previous 6 months</td>
<td>Supervised IG1: Aerobic (upper and lower extremity ergometer cycle, treadmill) and resistive exercises (weight machines, 6 exercises). Self-directed IG2: Received oral, written and practical instruction in 8 resistance exercises using elastic bands of differing resistance</td>
<td>4 weeks</td>
<td>3 days/week</td>
<td>20-30 min aerobic training + resistance exercise IG1: Aerobic intensity on cycle or treadmill 60-75% and resistance exercise 1-3 sets of 10 rep. IG2: 8 resistance exercises 1-3 sets of 10-15 rep. Patient was instructed to increase</td>
</tr>
<tr>
<td>Authors</td>
<td>Sample</td>
<td>Age</td>
<td>Design and study period</td>
<td>Exercise-based Intervention</td>
<td>Duration</td>
<td>Frequency/Intensity</td>
<td>Results</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------------------</td>
<td>----------------------</td>
<td>-------------------------</td>
<td>----------------------------</td>
<td>----------</td>
<td>--------------------</td>
<td>----------------------------------------------------------------------</td>
</tr>
</tbody>
</table>
| Inoue et al. 2010 | N= 26
Attrition 0%
26 completers:
IG1=13
IG2=13
Allo-HSCT
Hematopoietic diagnoses: AML, AIL, CML,
NHL, AA, MDS | 48.5 years* (range 20-62)
IG1: 43 (20-55)
CG: 54 (27-62)
Convenience sample – two different treatment groups receiving same intervention
IG1: myeloablative
IG2: nonmyeloablative
In-patient
Exercise initiated after neutrophil engraftment until discharge | Supervised
Aerobic exercise on cycle ergometer, and walking in a corridor, muscle strength (3 large muscle groups) and stretching (5 exercises)
IG1 approx. 12 weeks
IG2 approx. 8 weeks
Exact duration not reported: Program started after neutrophil engraftment
IG1: median 17 days (median hosp. days 101)
IG2: median 14 days (median hosp. days 71)
5 days/week
20-40 min
Aerobic exercise on cycle ergometer 60% MHR strength and stretching exercises modified according to patients activity level and condition | walking up to 30 consecutive min. 3x/wk. | IG2 † 6MWD 9.8% (p<0.05)
**Fatigue**
No significant difference in fatigue levels between groups, however there was a 20 and 10% decrease in fatigue scores in the supervised and unsupervised groups, respectively. |

| Wiskenmann et al. 2010 | N= 105
Attrition 24%
80 completers: IG1=40
CG=40 | 48.8 years* (range 18-71)
IG: 47.6 (18-70)
Allocation through minimization method - multicenter
IG: Partly supervised exercise program | Partly supervised (in-patient)
Self-directed (at home)
Introduction to program and training | 16 weeks
Prior HSCT
IG: 3 weeks
CG: 2 weeks
During HSCT | 5 sessions/week
(3-5 endurance and 2 resistance training sessions) | Light aerobic activity | Program compliance: 87.3%
(79% of exercise logs were returned)
Prior HSCT: 87.5%
During HSCT: 83% |
## Results

**www.intechopen.com**

A Systematic Review of Nonpharmacological Exercise-Based Rehabilitative Interventions in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

<table>
<thead>
<tr>
<th>Authors</th>
<th>Sample</th>
<th>Age</th>
<th>Design and study period</th>
<th>Exercise-based Intervention</th>
<th>Duration</th>
<th>Frequency/Intensity</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baumann et al. 2011</td>
<td>N=47 patients Attribution 30% 33 completers IG=17 CG=16 Allo-HSCT</td>
<td>42.1 years* (range 28-57)</td>
<td>RCT - two exercise groups</td>
<td>Supervised</td>
<td>IG: 4.5 weeks CG 3.8 weeks</td>
<td>5 days/week</td>
<td>After HSCT: 91.3%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IG: 41.4 (±11.78) CG: 42.8 (±14.04)</td>
<td>IG: Aerobic endurance cycle ergometer ADL including strength, coordination stretching, walking and stair climbing</td>
<td>IG: 2 sessions/ day aerobic 20-30 min/day interval training, RPE: 80% of achieved watt load in WHO-test. ADL: 20 min/day RPE: slightly strenuous</td>
<td></td>
<td></td>
<td>Safety: Not reported</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CG: standard care (PT) In-patient Initiated after stem cell infusion</td>
<td>CG: Mobilization 10 min, (gymnastics and coordination training), and stretching 5 min.</td>
<td>CG: 20 min/day</td>
<td></td>
<td>PRO for HR-QoL Pre-post</td>
<td>Significant intergroup differences in favor of IG: IG↓ and CG↑ general and physical fatigue (p=0.009, p=0.01) MFI-20. IG↓ and CG↑ fatigue (p=0.01) POMS. IG↓ and CG↑ physical functioning (p=0.03) EORTC IG↓ and CG↑ depression (p=0.05) POMS. Significant intergroup difference in favour of CG: IG↑ and CG↓ anxiety (p=0.01) HADS.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IG: Standard care - PT 3 days/week 30 min./session during hospitalization, step counters to record physical activity</td>
<td>manual incl. exercise DVD. Individualized exercise program includes aerobic warm-up, endurance and strength training. Contraindications for Intervention: Platelet ≤100-20 x 10^9/l Hemoglobin &lt; 8 g/dl Temp: &gt;38°C Pain, nausea and dizziness</td>
<td>IG 6 weeks CG 6 weeks After HSCT IG 7 weeks CG 7.5 weeks</td>
<td>and stretching Endurance training: walking/cycle 15-40 min Strength training: stretch bands 8-20 rep., 2-3 sets. Three different protocols were applied, 1) focus on extremities, 2) entire body and 3) bed exercises (in-patient)</td>
<td>Endurance RPE 12-14 Resistance RPE 14-16</td>
<td>Physiological Outcomes Pre-post No significant differences between exercise groups, however CG↓ aerobic endurance (p=0.009)</td>
</tr>
</tbody>
</table>
Table 3. Physical exercise based studies in allogeneic HSCT on aerobic capacity, muscle strength, health-related quality of life and treatment related symptoms

<table>
<thead>
<tr>
<th>Authors</th>
<th>Sample</th>
<th>Age</th>
<th>Design and study period</th>
<th>Exercise-based Intervention</th>
<th>Duration</th>
<th>Frequency/Setting</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Contraindications for exercise: Platelets &lt;10-20 x 10^9 /l Hemoglobin &lt;8 g/dl Temp: &gt;38°C Strong pain, infection, restricted consciousness, somnolence, confusion, dizziness, nausea and vomiting. Training was interrupted during cardio- and nephrotoxic chemotherapy.</td>
<td></td>
<td>RPE: Low intensity not strenuous.</td>
</tr>
</tbody>
</table>

*median age

AA indicates aplastic anemia, AML, acute myelogenous leukemia; ALL, acute lymphocytic or lymphoblastic leukemia; CML, chronic myelogenous leukemia; CMML, chronic myelomonocytic leukemia; MDS, myelodysplastic syndrome; MF, myelofibrosis; MM, multiple myeloma; MPS, myeloproliferative syndrome; HD, Hodgkins disease; NHL, Non-Hodgkin lymphoma; PNH, paroxysmal nocturnal hemoglobinuria; WM, waldenstrom macroglobulinemia

RPE, Rate of Perceived Exertion; St.v, Stroke Volume; HR, Heart Rate; IG, Intervention Group; IG2, Intervention Group 2; CG, Control Group; TPN, Total Parenteral Nutrition; MHR, Maximal Heart Rate; DM and NDM, Dominant Non Dominant; KPS, Karnofsky Score; PT, Physical therapy; PRO, patient reported outcome; HR-QoL, health related Quality of Life; TR-symptoms, treatment related symptoms; SCT-SAS, Stem cell transplantation-Symptom Assessment Scale; EORTC-QLQ-C30 European Organization for Research and Treatment of Cancer Quality of Life Questionnaire; HADS, Hospital Anxiety and Depression Scale; FACT-An or FACT-F, Functional Assessment of Cancer therapy-Anemia or Fatigue scale; POMS, Profile of Mood States; MFI, Multidimensional Fatigue Inventory; BFI, Brief Fatigue Inventory; BDI, Beck Depression Inventory; STAI, State Trait Anxiety Inventory; 6MWD, 6 minute walk distance, → no change; ↑ increase; ↓ decrease.
3. Results

3.1 Exercise-based studies in the allo-HSCT setting
In this review, 10 studies met the inclusion criteria (Baumann et al. 2011; Carlson et al. 2006; Cunningham et al. 1986; Defor et al. 2007; Inoue et al., 2010; Jarden et al., 2009; Kim and Kim 2006; Mello et al. 2003; Shelton et al. 2009; Wiskemann et al. 2011). Of these, three were from the USA and two from Germany, and respectively, one from Brazil, Canada, Denmark, Japan and South Korea. Cunningham et al. carried out the very first exercise training trial for the allo-HSCT population in 1986 and although the participants included children and adults (range 14 – 41 years), this study is included in the review because of its focus being in the allo-HSCT setting only. Jarden et al. published three articles and Kim et al. two articles, each based on one trial, however each article has a different focus and purpose.

All studies were designed as prospective intervention trials that tested an exercise-based program. The primary and secondary outcomes were study feasibility and safety; physiological outcomes i.e. aerobic, muscle strength and function; psychosocial outcomes i.e. health-related QoL, emotional wellbeing; treatment-related symptoms i.e. fatigue; and hospital or disease-related outcomes i.e. days of hospitalization, creatinine excretion, lymphocyte counts. Baseline to post assessment ranged between 4 – 16 weeks [mean 7.3] and one study had follow-up tests to 6 months (Jarden et. al. 2009).

3.2 Sample characteristics
In all, 406 patients with different haematological diseases (AA,, AML, ALL, CLL , CML, CMML, FL, HD, MDS, MF, MM, MPS, NHL, PNH, WM, other lymphomas) across 10

Table 4. Intervention phase

| Pre-conditioning → Admission/Conditioning → Stem cell transplant → Engraftment → Hospital discharge → 6 mo.+ → 24mo+ |
| Baumann | Cunningham | Defor | Jarden | Kim | Inoue | Mello |
| Carlson | Inoue |

1 AA indicates aplastic anemia, AML, acute myelogenous leukemia; ALL, acute lymphocytic or lymphoblastic leukemia ; CLL, chronic lymphocytic leukemia; CML, chronic myelogenous leukemia; CMML, chronic myelomonocytic leukemia; HD, Hodgkins disease; MDS, myelodysplastic syndrome; MF, myelofibrosis; MM, multiple myeloma; MPS, myeloproliferative syndrome; NHL, Non-Hodgkin lymphoma; PNH, paroxysmal nocturnal hemoglobinuria; WM, waldenstrom macroglobulinemia

www.intechopen.com
studies are included in this review. The sample size of the studies ranged from 12 to 105 [Mean 50.7] and the patients were of mixed gender between 14 and 71 years [mean 42.6]. Cunningham was the only study that included patients less than 18 years of age. Four studies were initiated prior to conditioning and throughout the hospitalization period (Baumann et al. 2011; Cunningham et al. 1986; Defor et al. 2007; Jarden et al. 2009; Kim and Kim 2006; Wiskemann et al. 2011), two studies after marrow engraftment and throughout hospitalization (Mello et al., 2003; Inoue et al., 2010), and three of these continued post allo-HSCT (Defor et al. 2007; Mello et al. 2003; Wiskemann et al. 2011). Two studies were initiated post allo-HSCT in the out-patient or home setting, within 6 and 39 months (range 9-92), respectively (Shelton et al. 2009; Carlson et al. 2006). The approximate start and endpoint of each intervention is illustrated in Table 4.

### 3.3 Type of exercise-based interventions

The duration of the exercise-based interventions ranged between 4-16 weeks [mean 7.3]. For interventions initiated prior to and during hospitalization, 6 of the studies were supervised (Cunningham et al. 1986; Mello et al. 2003; Kim and Kim 2006; Jarden et al. 2009; Inoue et al. 2010; Baumann et al. 2011) and 2 were partly supervised (DeFor et al. 2007, Wiskemann et al. 2011). In the out-patient context, Carlson’s study was fully supervised, while Shelton’s study had one supervised and one self-directed study arm. The frequency of all interventions ranged between 3 and 5 days/week or daily. When reported, the intensity of training in general was between low/mild and comfortable to moderate but not exceeding 70-75% of maximum heart rate or in Rate of Perceived Exertion (RPE) - being somewhat hard.

In the in-patient context, one study tested strength resistive training (Cunningham et al. 1986), one a walking program (treadmill or walking) (Defor et al. 2007) and another mixed-type low intensity bed exercises of stretching and relaxation breathing (Kim and Kim 2006), and 5 studies instituted mixed-type exercise up to moderate intensity (Mello et al. 2003, Jarden et al. 2009, Inoue et al. 2010, Wiskemann et al. 2011, Baumann et al. 2011) by combining aerobic training (treadmill, cycle, walking or stair climbing) with one or more other moderate intensity exercise (range of motion or ADL (activities of daily living), coordination exercises, muscle stretching, resistive exercises with free weights or elastic bands) and low intensity progressive relaxation training and education (Jarden et al. 2009). Three studies (Mello et al. 2003; Wiskemann et al. 2011, Defor et al. 2007) continued the programs after hospital discharge. In the out-patient only context, one study tested an ergometer cycle program (Carlson et al. 2006), and the other, aerobic (cycle or treadmill) and resistive exercises (weight machines) vs. self-directed walking and resistive exercises including patient information regarding exercise safety (Shelton et al. 2009). All in all, three studies were unidimensional (one exercise component), of which, two were aerobic training (Carlson et al. 2006; DeFor et al. 2007), and one resistance training (Cunningham et al. 1986), and seven studies had mixed type training (Baumann et al. 2011; Inoue et al. 2010; Jarden et al. 2009; Kim and Kim 2006; Mello et al. 2003; Shelton et al. 2009; Wiskemann 2011), of which, one was of low intensity (Kim and Kim 2006), and one study included both low and moderate intensity components (Jarden et al. 2009). Only two studies incorporated educational (Shelton et al. 2009) or psychoeducational (Jarden et al. 2009) elements in the program.
3.4 Feasibility and safety
No adverse events, reactions or injuries were reported, though not all studies reported safety outcomes. The overall attrition rates ranged between 0 and 44% (mean 18.7). Program compliance was reported by five studies (Carlson et al. 2006; DeFor et al. 2007; Jarden et al. 2009; Shelton et al. 2009; Wiskemann et al. 2011). Carlson et al. reported an overall 89% compliance. Defor et al. reported that 24% of all patients had 100% compliance and that 62% of the study’s population exercised at least 5 times/wk for at least 15 min during hospitalization and after discharge, respectively. Jarden et al. reported 90% intervention compliance (range 67-100), and 83% in-hospital and 87% at-home compliance (Wiskemann et al. 2011), while Shelton et al. reported 75% for the supervised intervention, though did not report for the self-directed intervention. Some studies had safety screening parameters, in which contraindication for exercise included platelet counts <10 and 20 x 10^9/l (Cunningham et al. 1986, Mello et al. 2003, Jarden et al. 2009; Wiskemann et al. 2011, Baumann et al. 2011), and haemoglobin <5 g/dl (Jarden et al. 2009), <8 (Wiskemann et al. 2011, Baumann et al. 2011), and <10 (Mello et al. 2003); temp>38°C (Cunningham et al. 1986; Jarden et al. 2009; Wiskemann et al. 2011, Baumann et al. 2011), and adverse symptoms as bleeding, petechiae, pain, nausea, dizziness. Baumann et al. interrupted training during cardio and nephrotoxic chemotherapy.

3.5 Physiological outcomes - aerobic/endurance
A mixed-type exercise program 5 days/week at moderate intensity during the entire hospitalization was able to maintain aerobic capacity, while the control group decreased, and this difference was highly significant (p<0.01) (Jarden et al. 2009). Another similar mixed-exercise program during hospitalization showed a significant decrease in aerobic endurance (p=0.009) in the control group, but no significant difference between intervention and control groups (Baumann et al. 2011). A 12 wk. aerobic training program on cycle ergometer initiated between 9 and 92 months after HSCT showed cardiovascular effects through increased stroke volume (p<0.005) and decreased heart rate (p<0.005), with a decreased RPE (p<0.005) (Carlson et al. 2006).

3.6 Muscle strength
Mello et al. combined aerobic (treadmill) and ROM exercise program initiated during hospitalization and continued into the outpatient facility over 6 weeks showed significant decrease in upper and lower extremity strength in the control group, however differences between intervention and control groups were not significant. During hospitalization, four muscle strength tests (chest press 1 RM, leg extension 1 RM, elbow flexor and knee extensor Newton) decreased by 2 - 4 % in the intervention group, while decreasing between 19 - 25 % in the control group. This difference was significant (p<0.01) (Jarden et al. 2009). Baumann et al., however, did not find a significant difference between groups for muscle strength, but the pre to post muscle strength scores decreased significantly in the control group (p=0.022).

3.7 Functional capacity
Wiskemann et al. maintained the 6 minute walk distance (6MWD) in the intervention group, while the control group decreased and the intergroup difference was significant (p=0.02). The 2 minute stair climb test in the intervention group decreased by 14 % and for the control
group 38%, and the difference between groups was significant \((p<0.01)\) (Jarden et al. 2009). A walking program did not show significant differences between groups for the Karnofsky score, though a subgroup analysis of the nonmyeloablative conditioned patients showed that this patient group decreased significantly less than the control group \((p=0.04)\) (DeFor et al. 2007). There were no significant differences for the 6MWD between a supervised and self-directed intervention, still both groups significantly improved by 12% \((p<0.05)\) and 9.8% \((p<0.05)\), respectively (Shelton et al. 2009). Also, the supervised group improved the 50 foot walk time \((p=0.05)\) and maintained other performance tests, though no significance between groups.

3.8 Health-related quality of life

A bed exercise study with relaxation breathing, ROM and stretching during hospitalization decreased depression (BDI) \(p=0.0001\) and anxiety (STAI) \(p=0.0001\) as compared to the control group (Kim and Kim 2006). An in- to out-patient walking program showed improvements in physical and emotional wellbeing on a self reported score from 1 – 10, with 1 being very poor and 10 being very good. At discharge, physical wellbeing was better in the exercise group \((p<0.01)\). Among the nonmyeloablative group, emotional wellbeing was better in the exercise group \((p=0.02)\) at discharge and at 100 days, physical wellbeing was superior in the exercise group \((p<0.01)\) (DeFor et al. 2007). A mixed exercise intervention during the entire hospitalization showed no difference in QoL and emotional wellbeing between groups (EORTC-QLQ-C30, FACT-An, HADS), though HRQOL was maintained in the intervention group at post testing, and there was significant improvement in emotional wellbeing at 3 and 6 months, \(p=0.045\) and \(p=0.012\), respectively (FACT-An) and significant decrease in anxiety at 3 and 6 months, \(p=0.021\) and \(p<0.0001\), respectively (HADS). The control group significantly decreased overall HRQOL \(p=0.0005\) (FACT-An) at post testing, and significantly reduced physical functioning \((p=0.004)\) and worsened three gastrointestinal symptoms (nausea and vomiting \((p=0.048)\), appetite loss \((p=0.004)\) and diarrhea \((p=0.011)\) (EORTC QLQ C-30) (Jarden et al. 2009). Wiskemann et al. study beyond discharge showed between group differences in favor of the intervention group in physical functioning \((p=0.03)\) (EORTC-QLQ-C30) and decreased depression \((p=0.05)\), though showed a significant increase in anxiety \((p=0.01)\) in the intervention group (HADS). Baumann et al. found no significant difference between groups on the EORTC-QLQ-C30, though the pre-post differences in the intervention and control group decreased significantly for physical functioning \((p=0.005\) and \(p=0.002)\). Intervention group improved emotional state \((p=0.028)\), but again, no differences between groups (Baumann et al. 2011). Carlson et al.’s out-patient endurance program significantly improved intergroup vigor scores \((p<0.001)\) on POMS.

3.9 Treatment-related symptoms

There was a decreased symptom prevalence in diminished concentration, memory loss, nausea and nervousness \((p<0.01)\) and decreased symptom severity in fatigue, loss of appetite, sleep difficulties and nausea \((p<0.05)\) on the SCT-SAS scale (Jarden et al. 2009). Further, diarrhea was significantly decreased (EORTC-QLQ-C30) \((p=0.014)\) (Jarden et al. 2009). Symptom cluster analyses revealed a significant decrease in symptom severity in gastrointestinal, cognitive, functional and mucositis clusters over time and up to 6 months after allo-HSCT \((p<0.01)\). Wiskemann et al. found a significant decrease between groups in both general and physical fatigue \((p=0.009, p=0.01)\) MFI and a significant decrease in fatigue
A Systematic Review of Nonpharmacological Exercise-Based Rehabilitative Interventions in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

(p=0.01) (POMS). Baumann et al. was unable to show between group differences in fatigue scores, but the control group increased fatigue at post testing (p=0.046). Carlson et al. showed a significant decrease in fatigue (p<0.001) (BFI and FACT-F).

3.10 Medical related outcomes
Cunningham et al. did not find significant changes in body composition, though a decreased creatinine excretion in the intervention group (Cunningham et al. 1986). Kim et al. tested a bed exercise effect on lymphocyte counts, and reported no significant differences between groups, however there was an interaction between groups and times (p=0.031), there was also a decrease in lymphocyte count in the control group (p<0.05). Jarden et al. reported the intervention group as receiving fewer days of TPN (p=0.019) with no changes in BMI between groups at post testing. There were no other differences between groups regarding hospitalization days, bone marrow engraftment days, days with fever, and though there was a 19% difference in the incidence of GvHD favoring the intervention group, this was not statistically different. Defor et al. and Inoue et al. showed no difference in days of hospitalization between groups, but Inoue et al. showed that the degree of physical activity had a negative correlation with the duration of hospitalization (r=-.71; p=0.0071).

3.11 Methodological quality of the studies
Seven studies were designed as randomized trials (Cunningham et al. 1986; Mello et al. 2003; Kim and Kim 2006; Defor et al. 2007; Jarden et al. 2009; Shelton et al. 2009; Baumann et al. 2011), one study allocated through the minimization method (Wiskeman et al. 2011), one study was a convenience sample studying the effect of the same exercise intervention on two different allo-HSCT treatment groups (myeloablative or nonmyeloablative conditioning regime) (Inoue et al. 2010) and one study did not have a control group (Carlson et al. 2006). Further, Shelton et al. studied the effect of two different interventions (supervised vs. self directed) in the outpatient/home setting. The control group was described in most studies as receiving standard or usual care, including either no formal training or the hospital units’ standard physical therapy (PT). Generally, standard PT was described as being introduced later during hospitalization, i.e. after stem cell infusion, and at less frequent intervals and lower intensity levels. The study arms were not similar at baseline in two (Kim and Kim 2006; Baumann et al. 2011) of the eight groups in which there was an intervention and control group present. The control group in Kim et al. had a significant higher lymphocyte level at baseline compared to the intervention group and Baumann et al. had twice as many males as females in the exercise group as compared to the control group at baseline. All studies reported the eligibility criteria to which the study population was chosen. Only one study stated that the outcome assessor was blinded (DeFor et al. 2007). In the relevant studies, none reported blinding of the exercise trainer or the patients. Two studies reported performing intention-to-treat analyses (Jarden et al. 2009; Wiskemann et al. 2011).

4. Summary
This is the first literature review of exercise-based interventions in the allo-HSCT context. The purpose of this systematic review was to summarize the exercise-based rehabilitative interventions in adults with haematological disease undergoing allogeneic hematopoetic
stem cell transplantation (allo-HSCT) on feasibility and safety, and effectiveness related to physical and functional capacity, health related quality of life, treatment-related symptoms and medical related outcomes. To date, 10 intervention studies and 13 articles have been published that incorporated exercise-based regimes in the allo-HSCT context, and though we have found encouraging and important results, making direct trial comparisons can be a challenge due to the small sample sizes, the wide range of different primary and secondary outcomes and measurements, varying types of interventions, and different start and end points, duration, frequency and intensity of the different exercise components. Most of the studies in this review were randomized trials, however, control groups received varying standard care regimes, and there was a lack of outcome assessor blinding, trainer blinding and patient blinding which decreases the general methodological quality of the studies. Taking these methodological limitations into consideration, this review however finds important results pertinent to the allo-HSCT clinical setting.

The results suggest that exercise interventions are feasible and safe. No study reported adverse events as a direct result of testing or exercising, though not all studies reported safety. Five studies reported safety screening parameters, which may have contributed to patients being able to exercise safely. Of the five studies that reported compliance rates, it would suggest that patients are capable of participating adequately in a daily exercise program during and after allo-HSCT. Two mixed type exercise studies implemented during the entire hospitalization suggest a stabilization in aerobic endurance during hospitalization (Jarden et al. 2009; Baumann et al. 2011), and one 12 week out-patient endurance study found significant positive cardiovascular effects (Carlson et al. 2006). In regards to muscle strength, mixed type exercise during hospitalization (Baumann et al. 2011; Jarden et al. 2009) and continuing in the outpatient context (Mello et al. 2003) showed significant muscle strength decreases in control group, but only one study found significant differences between groups (Jarden et al. 2009) suggesting that the loss of muscle strength was minimized. Mixed type exercise during hospitalization (Jarden et al. 2009) and continued after discharge (Wiskemann et al. 2011) significantly decreased loss of function (2 minute stair climb) (Jarden et al. 2009) and significantly maintained function (6MWT) (Wiskemann et al. 2011). DeFor et al.’s walking program during and after discharge did not show significant differences between groups for Karnofsky score, though a subgroup analysis of the nonmyeloablative group showed a significant reduction in loss of performance in the intervention group. (DeFor et al. 2007). Both supervised and self directed mixed type exercise in the post HSCT was shown to improve function significantly on the 6MWD and for the supervised group improvement was reported for the 50 foot walk time (Shelton et al. 2009). A mixed type low intensity exercise program during hospitalization significantly decreased depression (BDI) and anxiety as compared to the control group (Kim and Kim 2006), while two mixed-type moderate intensity exercise programs during hospitalization did not show a significant effect on HR-QoL (Baumann et al. 2011, Jarden et al. 2009), but Wiskemann et al.’s mixed type exercise that continued after discharge showed a significant improvement in physical functioning and decreased depression, but also a significant increase in anxiety (Wiskemann et al. 2011). DeFor’s in- to out-patient walking program reported significant improvements in emotional wellbeing among the nonmyeloablative patient group at hospital discharge and by 100 days, physical wellbeing was significantly improved. Carlson et al.’s 12 week out-patient endurance program significantly increased vigor. There was a significant longitudinal decrease in prevalence and intensity of several
symptoms and symptom clusters, including fatigue up to 6 months (Jarden et al. 2009) and in two studies exercising after discharge, a significant decrease in fatigue scores was reported (Wiskemann et al. 2011, Carlson et al. 2006). Hospital or treatment-related outcomes as body composition or immunological and infectious parameters i.e. lymphocyte counts, days to bone marrow engraftment, days with fever, incidence of GvHD., number of transfusions received) was not affected by exercise. One exercising group received significantly fewer days of TPN as compared to the control group (Jarden et al. 2009). There was no effect on duration of hospitalization (Inoue et al. 2010, Jarden et al. 2009, Defor et al. 2007), though Inoue et al. reported that the level of physical activity had a negative correlation with the number of hospitalization days (Inoue et al. 2010).

It is suggested in recent literature that the optimal training program for persons with cancer combine both aerobic and muscle strength training (Neiman & Courneya, 2006, Courneya & Friedenreich, 2011). A review from 2008 of 15 exercise trials in the in-patient and out-patient HSCT setting, included patients in the allo-HSCT and HD-SCS context and resulted in tentative recommendations (Wiskemann & Huber, 2008): mixed exercise: endurance (up to daily) and resistance training (2-3 x/wk)), from 10 - 30 minutes at moderate intensity (BORG scale 12-14, 70-80% maximum HR) before, during and after hospitalization. In Liu et al. literature review from 2009 of physical exercise interventions in hematological cancer patients suggested it feasible to conduct exercise in this patient population, but concluded that there was a lack in methodological quality in the physical exercise studies and therefore effectiveness could not be established (Liu et al.). Recommendations based on a more recent review from 2011 of patients with mixed hematologic disease propose ‘supervised’ exercise during and after hematological cancer treatments 2 to 5 days per week, with adjustment for health conditions. Further, a combination of aerobic and resistance exercise is suggested, with a varying intensity between 40-70% of maximum heart rate and full body resistance exercises at 8-12 reps and 2-3 sets with slow progression over time. Health and neutropenic screening for exercise participation is also recommended according to Jones et al. (Battaglini 2011).

Exercise recommendations, however for patients during and after hospitalization for specifically allo-HSCT have not been developed, and in order to determine the appropriate and optimal exercise prescription / intervention for patients undergoing allo-HSCT, trials in the allo-HSCT context were examined in this review for type, duration, frequency and intensity. Taken the methodological limitations into consideration, a partly to fully supervised and daily, mixed-type exercise (aerobic and resistant exercises, also ROM and stretching) at moderate intensity (70-75% MHR) started at least prior to conditioning and carried out during allo-HSCT is feasible and can maintain or decrease loss of aerobic capacity, muscle strength and function at hospital discharge. However, continuing the program after hospital discharge had further physical, functional and symptom related benefits (decrease fatigue, reduced depression). Attaining positive results require a relatively high compliance rate, over 85%. Therefore, screening parameters and contraindication for training criteria should be instituted to not only keep the patient safe, but also enable adequate participation in the program. Based on this review, it can be suggested that postponement or modification of training include: platelets < 20 x 10^9/l, haemoglobin < 5-8 g/l, temp > 38°C and adverse symptoms as bleeding, petechiae, pain, nausea, dizziness. It is not clear from this review, whether training during conditioning inkl. cardio and nephrotoxic chemotherapy should be postponed, and to what extent, that is, during active infusion or hours/days following chemotherapy. We may also consider
incorporation of low intensity exercise as relaxation breathing or progressive relaxation in the program, especially when a higher exercise intensity level is not possible (Kim and Kim, 2006; Jarden et al. 2009). Psychosocial, educational and motivational approaches may be integrated to maintain compliance levels, support exercise motivation and efficacy and increase independent activity and lifestyle changes.

5. Conclusion and future research

This chapter is a systematic review of the rehabilitation research carried out in the allo-HSCT context during the past 25 years. These findings, despite a number of methodological issues, indicate positive physiological and emotional benefits from exercise in patients during and after allo-HSCT. Exercise during treatment may help patients decrease loss of or maintain aerobic and functional capacity, and muscle strength, and when exercise is continued or instituted in the outpatient/home context there are improvements in aerobic and functional capacity. These results also indicate that exercise-based interventions have multidimensional benefits, including maintaining or improving HRQOL and reducing the most persistent treatment-related symptoms, especially fatigue. This review provides general guidelines for exercise in the allo-HSCT context. However, with improved methodological approaches, future research may provide clinicians with more specific rehabilitation guidelines.

5.1 Future research

Future studies are encouraged to institute certain methodological stringencies, including inclusion of homogenous groups (same diagnosis or treatment group), larger patient populations, perhaps, multi-institutional studies, randomized designs that clearly describe treatment allocation and stratification methods, as well as details regarding the control group. Further, point estimates for primary outcomes, effect size calculations, as well as Intention-to-Treat analyses are recommended. When and if possible, an effort to blind outcome assessors, data entry keyers and statisticians would improve methodological quality. It is also important that future studies justify the chosen intervention and clearly describe the individual exercise components duration, intensity and frequency as well as screening parameters for intervention participation, and lastly, documentation of compliance rates in order to properly evaluate the effect of the intervention. Decisions regarding test time-points and the most relevant and comprehensive outcome measurements need to be associated with challenges directly related to allo-HSCT. Therefore, GvHD, treatment related symptoms i.e. fatigue, insomnia, pain, gastrointestinal complaints, skin and bodily changes, poor physical, functional and muscle capacity, low levels of physical activity and decreased bone density, low Vitamin D levels and reduced HRQOL including problems with sexuality, body image, social wellbeing and job function need to be considered in this treatment group. More studies are needed that examine the entire treatment trajectory and continue well into the out-patient and home setting. Research that aims to promote multidimensional benefits may consider multimodal interventional designs that combine physical exercise with other psychosocial and educational approaches. Additionally the role of vitamin D and exposure to sunlight in combination with physical exercise on bone health, function and general wellbeing may be warranted. Further, there is
a need to study the patients’ own experience as a participant in an exercise-based intervention in order to develop programs that are tailored to fit the needs of patients during and after allo-HSCT. Finally, translational intervention studies are needed that support and improve the ability of patients to cope with their life situation during treatment, as well as to function optimally after allo-HSCT in daily life, including return to employment.

6. Conflict of interest
The author declares no conflict of interest.

7. Acknowledgements
I thank Anders Larsen (Information specialist - The University Hospital’s Centre for Nursing and Care Research, Copenhagen Denmark) for verifying and assisting with the literature search strategy. I would also like to thank Kristine Marie Jarden (Research assistant - University of Southern Denmark) for her assistance in manuscript preparation.

8. References


This book documents the increased number of stem cell-related research, clinical applications, and views for the future. The book covers a wide range of issues in cell-based therapy and regenerative medicine, and includes clinical and preclinical chapters from the respected authors involved with stem cell studies and research from around the world. It complements and extends the basics of stem cell physiology, hematopoietic stem cells, issues related to clinical problems, tissue typing, cryopreservation, dendritic cells, mesenchymal cells, neuroscience, endovascular cells and other tissues. In addition, tissue engineering that employs novel methods with stem cells is explored. Clearly, the continued use of biomedical engineering will depend heavily on stem cells, and this book is well positioned to provide comprehensive coverage of these developments.

How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:

© 2012 The Author(s). Licensee IntechOpen. This is an open access article distributed under the terms of the Creative Commons Attribution 3.0 License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.